| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
210,690,000 |
| Market
Cap: |
1.27(B) |
| Last
Volume: |
11,363,101 |
Avg
Vol: |
11,279,325 |
| 52
Week Range: |
$1.94 - $6.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
208,225 |
228,225 |
| Total Buy Value |
$0 |
$0 |
$535,647 |
$594,719 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
4 |
| Total Shares Sold |
20,000 |
20,000 |
20,000 |
20,000 |
| Total Sell Value |
$121,220 |
$121,220 |
$121,220 |
$121,220 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2025-10-02 |
2025-07-01 |
2024-12-31 |
2024-01-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ramsay David A |
|
– • – |
2025-12-19 |
4 |
S |
$6.06 |
$121,220 |
D/D |
(20,000) |
2,533,642 |
|
0% |
|
| Lowrance David L |
Chief Financial Officer |
• – – |
2025-12-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
32,000 |
286,045 |
|
- |
|
| Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-12-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
128,995 |
1,188,050 |
|
- |
|
| Erickson Anne |
Chief Business Officer |
• – – |
2025-12-14 |
4 |
D |
$6.92 |
$435,683 |
D/D |
(62,960) |
371,712 |
|
- |
|
| Lowrance David L |
Chief Financial Officer |
• – – |
2025-12-14 |
4 |
D |
$6.92 |
$435,683 |
D/D |
(62,960) |
318,045 |
|
- |
|
| Lutz Robert Matthew |
Chief Operating Officer |
• – – |
2025-12-14 |
4 |
D |
$6.92 |
$468,899 |
D/D |
(67,760) |
293,977 |
|
- |
|
| Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-12-14 |
4 |
D |
$6.92 |
$1,354,279 |
D/D |
(195,705) |
1,317,045 |
|
- |
|
| Mccabe Kathleen R. |
Chief Legal Officer |
• – – |
2025-12-14 |
4 |
D |
$6.92 |
$272,302 |
D/D |
(39,350) |
519,232 |
|
- |
|
| Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-12-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
23,629 |
1,512,750 |
|
- |
|
| Mccracken Joseph S |
|
– • – |
2025-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
300,837 |
|
- |
|
| Van Es-Johansson An |
|
– • – |
2025-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
102,500 |
|
- |
|
| Elam Nevan C |
|
– • – |
2025-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
106,887 |
|
- |
|
| Ramsay David A |
|
– • – |
2025-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
2,553,642 |
|
- |
|
| Hawkins Richard J |
|
– • – |
2025-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
161,326 |
|
- |
|
| Wasfi Yasmine |
Chief Medical Officer |
• – – |
2025-12-04 |
4 |
D |
$6.37 |
$140,089 |
D/D |
(21,992) |
168,008 |
|
- |
|
| Elam Nevan C |
|
– • – |
2025-12-02 |
4 |
D |
$5.81 |
$8,558 |
D/D |
(1,473) |
66,887 |
|
- |
|
| Elam Nevan C |
|
– • – |
2025-12-02 |
4 |
OE |
$1.46 |
$8,556 |
D/D |
5,860 |
68,360 |
|
- |
|
| Hawkins Richard J |
|
– • – |
2025-11-14 |
4 |
OE |
$1.46 |
$8,556 |
D/D |
5,860 |
121,326 |
|
- |
|
| Wasfi Yasmine |
Chief Medical Officer |
• – – |
2025-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
190,000 |
|
- |
|
| Wasfi Yasmine |
Chief Medical Officer |
• – – |
2025-10-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
155,000 |
|
67% |
|
| Hawkins Richard J |
|
– • – |
2025-06-20 |
4 |
B |
$2.04 |
$98,572 |
D/D |
48,225 |
115,466 |
0.01 |
114% |
|
| Mccracken Joseph S |
|
– • – |
2025-05-29 |
4 |
B |
$2.08 |
$20,825 |
D/D |
10,000 |
260,837 |
0.01 |
53% |
|
| Ramsay David A |
|
– • – |
2025-03-31 |
4 |
B |
$2.78 |
$416,250 |
D/D |
150,000 |
2,513,642 |
0.01 |
-5% |
|
| Mccabe Kathleen R. |
Chief Legal Officer |
• – – |
2025-03-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
558,582 |
|
-10% |
|
| Lutz Robert Matthew |
Chief Operating Officer |
• – – |
2025-02-13 |
4 |
D |
$2.83 |
$108,284 |
D/D |
(38,263) |
361,737 |
|
- |
|
211 Records found
|
|
Page 1 of 9 |
|
|
0.08 (1.31%) 
